Suhyun Kang, PhD

Eli Lilly and Company, Indianapolis, IN, USA

Poster(s):

• 1512 - Pirtobrutinib after a Covalent BTK Inhibitor in Pretreated Chronic Lymphocytic Leukemia: A Phase 2 Dose Optimization Trial in Progress